China channel feed

Biose­cure bill is left out of end-of-year de­fense pack­age, deal­ing blow to chances

7 months ago
FDA+
Manufacturing

GSK makes an­oth­er ADC deal, this time with BioN­Tech's part­ner Du­al­i­ty­Bio

7 months ago
Deals
Pharma

Sanofi ear­marks €1B for new in­sulin pro­duc­tion fac­to­ry in Bei­jing   

7 months ago
Manufacturing

Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo taps Shang­hai biotech for ADC, adds new funds

7 months ago
Startups
Deals

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

7 months ago
Pharma

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

7 months ago
Deals
Pharma

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

7 months ago
Deals
Pharma

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

7 months ago
Pharma

Mer­ck KGaA plans Chi­na sub­mis­sion af­ter late-stage win for tu­mor drug

7 months ago
R&D

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

8 months ago
Financing
Pharma

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

8 months ago
People
Pharma

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

8 months ago
Startups
Deals

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

8 months ago
People
AI

Bax­ter pulls IV prod­ucts out of Chi­na to shift sup­ply to the US

8 months ago
Manufacturing

Gar­dasil de­mand in Chi­na sinks, and Mer­ck ex­pects the same next quar­ter

8 months ago
Pharma

As­traZeneca Chi­na ex­ec probed by lo­cal au­thor­i­ties

8 months ago
Law

WuXi AppTec is still sign­ing on new clients de­spite Biose­cure threat

8 months ago
Manufacturing

BeiGene ex­ec­u­tive re­port­ed­ly un­der in­ves­ti­ga­tion in Chi­na

8 months ago
Pharma

Lawyers pre­dict Biose­cure pas­sage in lame duck ses­sion, but Sen­ate may de­cide key de­tails

8 months ago
Pharma
FDA+

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the draw­ing board’

8 months ago
Manufacturing
Law

Mer­ck KGaA eyes more man­u­fac­tur­ing M&A as it faces head­winds in Chi­na

8 months ago
Manufacturing

Clients add pres­sure to CD­MOs to source raw ma­te­ri­als out­side of Chi­na, ex­ecs say

9 months ago
Manufacturing

WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port

9 months ago
Deals

Ron Re­naud's new obe­si­ty biotech, Kail­era, has $400M to go straight to Phase 3

9 months ago
Financing
Startups
First page Previous page 1234567 Next page Last page
A service from the Financial Times